Document:

EX-10.8

 Exhibit 10.8 

CONSULTING SERVICES AGREEMENT 

THIS CONSULTING SERVICES AGREEMENT (this “Agreement”), is dated October 4, 2016 (the “Commencement
Date”), by and between Energy Future Holdings Corp. (“EFH”), a Texas corporation (the “Company”), and Andrew M. Wright, an individual (“Consultant”). 

WHEREAS, the Company desires to retain and engage Consultant, and Consultant desires to offer his knowledge and expertise, as the Executive
Vice President, General Counsel and Secretary (“General Counsel”) of the Company; and 
 WHEREAS, the Parties acknowledge
that the relationship between the Company and Consultant is an independent contractor relationship. 
 NOW, THEREFORE, in consideration of
the mutual covenants and agreements set forth herein, the Parties hereto agree as follows: 
 1. Appointment; Consulting Arrangement.
The Company hereby confirms Consultant’s appointment as General Counsel effective as of the Commencement Date. Consultant will (i) serve as the General Counsel of the Company and certain of its subsidiaries (and hold such other offices as
may be determined to be appropriate), (ii) have such duties, authority and responsibilities as shall be determined from time to time by the board of directors of the Company (the “Board”), which duties, authority and
responsibilities shall be customary for the General Counsel position in a business of similar size, type, circumstances and nature to that of the Company, including offering advice and counsel on legal matters, including restructuring, finance/
capital markets, regulatory, corporate governance and/ or communication matters; (iii) manage outside counsel and transition services provided by TEX Operations Company LLC; (iv) serve as a member of the board of directors/managers of
certain of the Company’s subsidiaries; and (vi) perform such other duties and responsibilities as shall be agreed upon between Consultant and the Company and/or the Board (collectively, the “Services”). 

2. Term, Termination and Other Service. 

(a) The term of Consultant’s tenure as General Counsel (the “Consulting Term”) commenced as of Commencement Date and
shall terminate on the EFH Effective Date as defined in the Fourth Amended Joint Plan of Reorganization of Energy Future Holdings Corp. et al, filed with the United States Bankruptcy Court for the District of Delaware on September 21, 2016, and
as may be amended from time to time (the “Expiration Date”). The Company or Consultant may terminate the Consulting Term prior to the Expiration Date by giving sixty (60) days prior written notice to the other party. 

(b) The Consultant agrees, to the extent necessary to reasonably discharge the Services, to use Consultant’s commercially reasonable
efforts and such time as is reasonably required to perform such duties and responsibilities. 
 (c) Upon termination of the Consulting Term,
Consultant shall be deemed to have resigned from all positions with the Company and its subsidiaries, including without limitation, all director, manager, and officer positions. 

  
 1 

 (d) Consultant may (i)(A) continue to serve on the boards of directors of the entities on which
he serves on the Commencement Date, and (B) serve on the boards of directors of any investment fund or other pooled investment vehicle that is a subsidiary or an affiliate of such entities, including, without limitation, any such subsidiary or
affiliate that may be formed after the date hereof, (ii) serve as a member of the board of directors of a reasonable number of other for-profit companies that do not compete with the Company, (iii) serve on civic, charitable, educational,
religious, public interest or public service boards, and (iv) manage Consultant’s personal and family investments. 
 3.
Compensation. 
 (a) Base Compensation. Consultant shall be paid in cash an annual advisory fee by the Company equal to
$1,500,000 per year (the “Base Fee”) in monthly installments of $125,000, payable on the first day of every calendar month during the Consulting Term for the preceding calendar month. 

(b) Termination. Upon termination or expiration of the Consulting Term, (i) Consultant shall be paid any Base Fee earned but not
paid to Consultant prior to the termination under Section 3(a), including a pro-rated portion of the Base Fee for the month in which the termination occurs (calculated as set forth below), which shall be paid as soon as practicable after
the end of the Consulting Term; and (ii) Consultant shall be entitled, subject to the requirements of Section 4(a), to receive reimbursement for any reasonable expenses incurred in connection with the performance of Services prior
to the end of the Consulting Term. The calculation of any Base Fee to be paid to Consultant under this Section 3(b) following termination of the Consulting Term shall be determined by multiplying $125,000 by a fraction, the numerator of
which is the number of days commencing on the first day of the month in which such termination occurred and ending on the date of termination and the denominator of which is the number of days in the month. 

4. Expenses and Administrative Support. 

(a) Business Expenses. In addition to the compensation payable to Consultant pursuant to Section 3 hereof, Consultant is
authorized to incur reasonable and customary business expenses incurred on the Company’s behalf in connection with the performance of Services hereunder, including, without limitation, expenditures for business travel, lodgings, meals and
entertainment expenses (“Business Expenses”). The Company shall, subject to the requirements of this Section 4(a), reimburse Consultant for all Business Expenses upon presentation by Consultant, from time to time, of
appropriately itemized accounts of such expenditures. Consultant shall provide such itemized accounts within sixty (60) days after the expense is incurred and the Company shall reimburse Consultant within fifteen (15) days after receipt of
such account. Expenses shall be reimbursed as soon as practicable following the Company’s receipt of such accounts, but in no event later than the March 15th following the end of the
calendar year in which the expenses were incurred; provided, however, the Company’s obligation to reimburse reasonable expenses will terminate in the event Consultant does not request reimbursement in a timely manner to allow the expense to be
paid prior to such date. 

  
 2 

 (b) Administrative Support. Consultant shall be provided with an office, parking space and
administrative assistant, each in Dallas, Texas, as well as any professional resources needed to discharge his responsibilities, in each case at the sole expense of the Company. 

5. Status; Taxes. 
 (a)
Status of Consultant. It is the intention of the parties hereto that, in performing the Services, Consultant shall act as and be deemed in all respects to be an independent contractor, and not for any purpose as an employee or agent of the
Company except on authority specifically so delegated to Consultant to act as agent, and he shall not represent to the contrary to any person. Consultant shall only consult, render advice and perform such tasks as Consultant determines are necessary
to provide the Services. Although the Company may specify the tasks to be performed by Consultant and may control and direct him in that regard, the Company shall not control or direct Consultant as to the details or means by which such tasks are
accomplished. 
 (b) Taxes. The Company shall withhold any income or employment taxes required by law to be withheld from payments
made hereunder, provided however, that Consultant shall have full responsibility for satisfying any other tax required by law to be paid with respect to the fees paid hereunder. 

(c) Consultant shall receive no employee benefits from the Company. 

6. Confidentiality, Non-Disclosure Agreement. The Company and the Consultant acknowledge and agree that during the Consultant’s
performance of Services, the Consultant will have access to and may assist in developing Confidential Information and will occupy a position of trust and confidence with respect to the affairs and business of the Company and the Affiliates. Pursuant
to 18 USC § 1833(b), an individual may not be held criminally or civilly liable under any federal or state trade secret law for disclosure of a trade secret: (i) made in confidence to a government official, either directly or indirectly,
or to an attorney, solely for the purpose of reporting or investigating a suspected violation of law; and/or (ii) in a complaint or other document filed in a lawsuit or other proceeding, if such filing is made under seal. Additionally, an
individual suing for retaliation based on the reporting of a suspected violation of law may disclose a trade secret to his or her attorney and use the trade secret information in the court proceeding, so long as any document containing the trade
secret is filed under seal and the individual does not disclose the trade secret except pursuant to court order. 

  
 3 

 The Consultant agrees that the following obligations are necessary to preserve the confidential
and proprietary nature of Confidential Information and to protect the Company and the Affiliates against harmful solicitation of employees and customers, harmful competition and other actions by the Consultant that would result in serious adverse
consequences for the Company and the Affiliates: 
 (a) Non-Disclosure. Consultant shall not, without the prior written consent of the
Company, use, divulge, disclose or make accessible to any other person, firm, partnership, corporation or other entity any Confidential Information pertaining to the business of the Company or its Affiliates, except (i) while providing Services
to the Company, in the business of and for the benefit of the Company, or (ii) as required by law, provided, however, that if Consultant receives a subpoena to produce any Confidential Information, Consultant will notify the Company promptly so
that the Company can seek a protective order, if desired. For purposes of this Section 6, “Confidential Information” shall mean information: (A) disclosed to or known by the Consultant as a consequence of or through
his engagement with the Company or any Affiliate; (B) not publicly available or not generally known outside the Company or any Affiliate; and (C) that relates to the business and/or development of the Company or any Affiliate. Any
information that does not meet each of the criteria listed above (in subsections (A) - (C)), other than by the Consultant’s breach of the terms hereof shall not constitute Confidential Information. By way of clarification (but not limitation),
information that the Consultant conceived or developed during his engagement with the Company or an Affiliate or learned from other employees or contractors of the Company or an Affiliate that meets the definition of Confidential Information shall
be treated as such. The Consultant acknowledges that the Confidential Information of the Company is valuable, special and unique to its business and is information on which such business depends, is proprietary to the Company, and that the Company
wishes to protect such Confidential Information by keeping it secret and confidential for the sole use and benefit of the Company. Consultant will take all commercially reasonable steps necessary and reasonably requested by the management of the
Company, to ensure that all such Confidential Information is kept secret and confidential for the sole use and benefit of the Company. 
  

	 	(b)	Non-Disparagement. 

  

	 	(i)	Consultant agrees not to defame, or make any false or disparaging statements about the Company and/or its Affiliates, or any of their respective products, services, finances, financial condition, capabilities or other
aspect of or any of their respective businesses, in any medium to any person or entity; or otherwise, to take any action that primarily is designed to have the effect of discouraging any employee, lessor, licensor, customer, supplier, or other
business associate of the Company from maintaining its business relationships with the Company and/or its Affiliates (any such statement or act a “Prohibited Statement” or “Prohibited Action”). Consultant shall be
permitted to make such statements or take such actions as are reasonably necessary in connection with Consultant’s duties and responsibilities under this Agreement, without such statements or actions being considered a Prohibited Statement or
Prohibited Action under this Agreement. 

  

	 	(ii)	The Company hereby agrees that Company and its officers shall not defame, or make any false or disparaging statements in any medium to any person or entity about Consultant. 

  
 4 

	 	(iii)	Notwithstanding any provision of this Section 6(b) to the contrary, (A) both Consultant and the Company (including the Board and its executive officers) may (1) confer in confidence with their
legal representatives and make truthful statements as required by law and (2) make private statements to any officer, director or employee of the Company or any of its affiliates; and (B) nothing herein shall prevent any person from
(1) responding publicly to incorrect, disparaging or derogatory public statements to the extent reasonably necessary to correct or refute such public statement or (2) making any truthful statement to the extent (x) necessary with
respect to any litigation, arbitration or mediation involving this Agreement or any other agreement among or between any party hereto or (y) required by law or by any court, arbitrator, mediator or administrative or legislative body (including
any committee thereof) with actual or apparent jurisdiction to order such person to disclose or make accessible such information. 

  

	 	(iv)	By signing this Agreement, the parties agree and acknowledge that they each are making, after the opportunity to confer with counsel, a knowing, voluntary and intelligent waiver of rights either may have to make
disparaging comments regarding the other party (and, as applicable affiliates thereof), including rights under the First Amendment to the United States Constitution and any other applicable federal and state constitutional rights. 

(c) Survival of Covenants. The non-disclosure and non-disparagement obligations contained in this Section 6 shall continue
in full force and effect after the conclusion of Consultant’s engagement with the Company and shall survive the expiration or termination of the Consulting Term, in each case in accordance with their respective terms, regardless of the reason
for such termination or restriction. Consultant’s obligations with respect to any specific Confidential Information shall cease only when that specific portion of the Confidential Information becomes publicly known, other than as a result of
disclosure by Consultant, in its entirety, without combining portions of such Confidential Information with other Confidential Information obtained separately. 

7. Indemnification. During the Consulting Term and thereafter, the Company agrees to indemnify and hold the Consultant and the
Consultant’s estate, heirs and representatives harmless, to the maximum extent permitted by law, against any and all damages, costs, liabilities, losses and expenses (including reasonable attorneys’ fees) as a result of any claim or
proceeding (whether civil, criminal, administrative or investigative), or any threatened claim or proceeding (whether civil, criminal, administrative or investigative), against the Consultant that arises out of or relates to the Consultant’s
Services, including as an officer, director or manager, as the case may be, of the Company, or the Consultant’s service in any such capacity or similar capacity with an affiliate of the Company or other entity at the request of the Company,
both prior to and after the Commencement Date, and to promptly advance to the Consultant or the Consultant’s estate, heirs or representatives such expenses upon written request with 

  
 5 

 
appropriate documentation of such expense upon receipt of an undertaking by the Consultant or on the Consultant’s behalf to repay such amount if it shall ultimately be determined that the
Consultant is not entitled to be indemnified by the Company. During the Consulting Term and thereafter, the Company also shall provide the Consulting Term with coverage under its current directors’ and officers’ liability policy to the
same extent that it provides such coverage to its other executive officers and directors. If the Consultant has any knowledge of any actual or threatened action, suit or proceeding, whether civil, criminal, administrative or investigative, as to
which the Consultant may request indemnity under this provision, the Consultant will give the Company prompt written notice thereof; provided that the failure to give such notice shall not affect the Consultant’s right to indemnification. The
Company shall be entitled to assume the defense of any such proceeding and the Consultant will use reasonable efforts to cooperate with such defense. To the extent that the Consultant in good faith determines that there is an actual or potential
conflict of interest between the Company and the Consultant in connection with the defense of a proceeding, the Consultant shall so notify the Company and shall be entitled to separate representation at the Company’s expense by counsel selected
by the Consultant who is reasonably acceptable to the Company, which counsel shall cooperate, and coordinate the defense, with the Company’s counsel and minimize the expense of such separate representation to the extent consistent with the
Consultant’s separate defense. This Section 7 shall continue in effect after the termination of the Consulting Term. 
 8.
Severability. If any provision of this Agreement shall be declared to be invalid or unenforceable, in whole or in part, such invalidity or unenforceability shall not affect the remaining provisions hereof which shall remain in full force and
effect. 
 9. Modifications. Any waiver, alteration, amendment or modification of any provisions of this Agreement shall not be valid
unless in writing and signed by the Company and the Consultant. 
 10. Assignment; Binding Effect. Neither party may assign any of
its or his rights or delegate any of its or his duties under this Agreement without the consent of the other and any attempted assignment in violation of this provision shall be void. 

11. Notice. All notices, demands, requests, or other communications which may be or are required to be given or made by any party to
any other party pursuant to this Agreement shall be in writing and shall be hand delivered, mailed by first-class registered or certified mail, return receipt requested, postage prepaid, delivered by overnight air courier service, or transmitted by
facsimile transmission addressed as follows: 
 If to the Company: 

Energy Future Holdings Corp. 

1601 Bryan Street 
 Dallas,
Texas 75201-3411 
 Attention: Chief Executive Officer 

  
 6 

 If to Consultant: 

Andrew M. Wright 
 At his home
address on record 
 or to such other addresses as a party shall designate in the manner provided in this Section 11. Any notice or other
communication shall be deemed given (a) on the date three (3) business days after it shall have been mailed, if sent by certified mail, (b) on the date one (1) business day after it shall have been given to a
nationally-recognized overnight courier service or (c) upon the electronic confirmation of facsimile. 
 12. Governing Law. This
Agreement shall be governed by and construed in accordance with the law of the State of Texas, without regard to conflicts of laws principles. The Parties agree that the proper venue and jurisdiction for any cause of action relating to the Agreement
shall be in Dallas County, Texas. If Consultant substantially prevails on his substantive legal claims, the Company shall reimburse all legal fees and costs incurred by the Consultant to resolve the dispute. 

13. Section Headings. The section headings contained in this Agreement are for reference purposes only and shall not affect in any way
the meaning or interpretation of this Agreement. 
 14. Counterparts. This Agreement may be executed in one or more counterparts
(including by facsimile), which shall, collectively and separately, constitute one agreement. 
 15. Section 409A. To the extent
applicable, this Agreement is intended to comply with, or be exempt from, section 409A of the Internal Revenue Code of 1986, as amended (the “Code”), and shall be administered, construed and interpreted in accordance with such
intent. Payments under this Agreement shall be made in a manner that will comply with, or be exempt from, section 409A of the Code, including regulations or other guidance issued with respect thereto, except as otherwise determined by the Company.
The applicable provisions of section 409A of the Code are hereby incorporated by reference and shall control over any contrary provisions herein that conflict therewith. 

16. Entire Agreement. This Agreement constitutes the entire agreement between the Parties respecting the employment of the Consultant
on and after the Commencement Date, there being no representations, warranties or commitments except as set forth herein and supersedes and replaces all other agreements related to the subject matter hereof. For the avoidance of doubt, this
Agreement does not supersede any agreement between Consultant and TCEH Corp. or any of its affiliates or predecessors. The Consultant acknowledges that, in connection with his entry into this Agreement, he was advised by an attorney of his choice on
the terms and conditions of this Agreement, including, without limitation, on the application of section 409A of the Code to the payments and benefits payable or to be paid to the Consultant hereunder. 

[Remainder of Page Intentionally Left Blank] 

  
 7 

 IN WITNESS WHEREOF, the undersigned have duly executed and delivered this Agreement, or have
caused this Agreement to be duly executed and delivered on their behalf. 
  

	
	
	/s/ Andrew M. Wright
	
	Andrew M. Wright
	
	ENERGY FUTURE HOLDINGS CORP.
	
	/s/ Paul Keglevic
	
	By: Paul Keglevic
	
	Its: President, Chief Executive Officer, Chief Restructuring Officer and Chief Accounting Officer

  
 8EX-4.1

 EXHIBIT 4.1 

NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE
SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), AND, ACCORDINGLY, EXCEPT AS SET FORTH IN SECTIONS 5.2, 5.3 AND 5.4 BELOW, MAY NOT BE OFFERED OR
SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND IN ACCORDANCE WITH
APPLICABLE STATE SECURITIES LAWS AS EVIDENCED BY, SUBJECT TO SECTIONS 5.2, 5.3 AND 5.4 BELOW, A LEGAL OPINION OF COUNSEL TO THE TRANSFEROR TO SUCH EFFECT, THE SUBSTANCE OF WHICH SHALL BE REASONABLY ACCEPTABLE TO THE COMPANY. 

WARRANT TO PURCHASE COMMON STOCK 

Company: CLEARSIDE BIOMEDICAL, INC. 
 Number of
Shares of Common Stock: [4% of term loan amount / Warrant Price] 
 Warrant Price: $[lesser of (i) the average closing price of
Company’s Common Stock for the 30 trading days ending on the day before the Issue Date or (ii) the ending price the day before the Issue Date] per share 

Issue Date:  
 Expiration Date: [Tenth
Anniversary of Issue Date]        See also Section 5.1(b). 

			
	Credit Facility:	  	This Warrant to Purchase Common Stock (“Warrant”) is issued in connection with that certain Amended and Restated Loan and Security Agreement of even date herewith between Silicon Valley Bank, MidCap Funding
XII Trust and MidCap Financial Trust and the Company (the “Loan Agreement”).

 THIS WARRANT CERTIFIES THAT, for good and valuable consideration, [Holder] (together with any successor
or permitted assignee or transferee of this Warrant or of any shares issued upon exercise hereof, “Holder”) is entitled to purchase the number of fully paid and non-assessable shares (the “Shares”) of
the above-stated common stock (the “Common Stock”) of the above-named company (the “Company”) at the above-stated Warrant Price, all as set forth above and as adjusted pursuant to Section 2 of
this Warrant, subject to the provisions and upon the terms and conditions set forth in this Warrant. [Reference is made to Section 5.4 of this Warrant whereby Silicon Valley Bank shall transfer this Warrant to its parent company, SVB
Financial Group.] 
 SECTION 1. EXERCISE. 

1.1 Method of Exercise. Holder may at any time and from time to time through the Expiration Date exercise this Warrant, in whole
or in part, by delivering to the Company the original of this Warrant (or evidence of loss, theft, mutilation or destruction of such original and the indemnity agreement described in Section 1.4 below, or a facsimile or 

  

 
electronic (pdf) copy of this Warrant pursuant to Section 5.5 below) together with a duly executed Notice of Exercise in substantially the form attached hereto as Appendix 1 (pursuant to Section
5.5 below) and, unless Holder is exercising this Warrant pursuant to a cashless exercise set forth in Section 1.2, within three (3) trading days (i.e., three consecutive days on which the principal Trading Market as defined in Section 1.3 below
is open for trading) following the date of exercise, a check, wire transfer of same-day funds (to an account designated by the Company), or other form of payment acceptable to the Company for the aggregate Warrant Price for the Shares being
purchased. 
 1.2 Cashless Exercise. On any exercise of this Warrant, in lieu of payment of the aggregate Warrant Price in the
manner as specified in Section 1.1 above, but otherwise in accordance with the requirements of Section 1.1, Holder may elect to receive Shares equal to the value of this Warrant, or portion hereof as to which this Warrant is being
exercised as set forth in the following sentence. Thereupon, the Company shall issue to the Holder such number of fully paid and non-assessable Shares as are computed using the following formula: 

X = Y(A-B)/A 
 where: 

 

	 	X =	the number of Shares to be issued to the Holder; 

  

	 	Y =	the number of Shares with respect to which this Warrant is being exercised (inclusive of the Shares surrendered to the Company in payment of the aggregate Warrant Price); 

 

	 	A =	the Fair Market Value (as determined pursuant to Section 1.3 below) of one Share; and 

  

	 	B =	the Warrant Price. 

 1.3 Fair Market Value. If the Company’s Common Stock is
then traded or quoted on a nationally recognized securities exchange, inter-dealer quotation system or over-the-counter market (a “Trading Market”), the fair market value of a Share shall be the closing price or last sale
price of a share of Common Stock reported for the Business Day immediately before the date on which Holder delivers this Warrant together with its Notice of Exercise to the Company. If the Company’s Common Stock is not traded in a Trading
Market, the Board of Directors of the Company shall determine the fair market value of a Share in its reasonable good faith judgment. Notwithstanding the foregoing, and whether or not the Company’s Common Stock is then traded in a Trading
Market, in the event Holder’s cashless exercise under Section 1.2 is exercised or deemed exercised in connection with an Acquisition, the Fair Market Value shall be determined, if such determination would result in a greater number of Shares
being issues upon such cashless exercise, based upon the cash and fair market value of any securities and other consideration as would have been paid for or in respect of each Share issuable (as of immediately prior to the closing of such
Acquisition) upon exercise of this Warrant as if such Share had been issued and outstanding on and as of the closing of such Acquisition). 

  
 2 

 1.4 Delivery of Certificate and New Warrant. Within a reasonable time after Holder
exercises this Warrant in the manner set forth in Section 1.1 or 1.2 above, the Company shall deliver to Holder a certificate representing the Shares issued to Holder upon such exercise and, if this Warrant has not been fully exercised and
has not expired, a new warrant of like tenor representing the Shares not so acquired. 
 1.5 Replacement of Warrant. On receipt
of evidence reasonably satisfactory to the Company of the loss, theft, destruction or mutilation of this Warrant and, in the case of loss, theft or destruction, on delivery of an indemnity agreement reasonably satisfactory in form, substance and
amount to the Company or, in the case of mutilation, on surrender of this Warrant to the Company for cancellation, the Company shall, within a reasonable time, execute and deliver to Holder, in lieu of this Warrant, a new warrant of like tenor and
amount. 
 1.6 Treatment of Warrant Upon Acquisition of Company. 

(a) Acquisition. For the purpose of this Warrant, “Acquisition” means any transaction or series of related
transactions involving: (i) the sale, lease, exclusive license, or other disposition of all or substantially all of the assets of the Company; (ii) any merger, reorganization or consolidation of the Company into or with another person
or entity (other than a merger, reorganization or consolidation effected exclusively to change the Company’s domicile), or any other corporate reorganization, in which the stockholders of the Company in their capacity as such immediately prior
to such merger, consolidation or reorganization, own less than a majority of the Company’s (or the surviving or successor entity’s, or if the surviving entity is a wholly-owned subsidiary of another corporation, such surviving
entity’s parent) outstanding voting power immediately after such merger, consolidation or reorganization; or (iii) any sale or other transfer by the stockholders of the Company of shares representing at least a majority of the
Company’s then-total outstanding combined voting power. For avoidance of doubt, “Acquisition” shall exclude any transaction in which the Company sells and issues its capital stock to venture capital investors, for capital raising
purposes, in a bona fide round of preferred stock financing. 
 (b) Treatment of Warrant at Acquisition. In the event of an
Acquisition in which the consideration is to be received by the Company’s stockholders and consists solely of cash, solely of Marketable Securities or a combination of cash and Marketable Securities (a “Cash/Public
Acquisition”), and the fair market value of one Share as determined in accordance with Section 1.3 above would be greater than the Warrant Price in effect on such date immediately prior to such Cash/Public Acquisition, and Holder
has not exercised this Warrant pursuant to Section 1.1 above as to all Shares, then this Warrant shall automatically be deemed to be Cashless Exercised pursuant to Section 1.2 above as to all Shares effective immediately prior to and
contingent upon the consummation of a Cash/Public Acquisition. In connection with such Cashless Exercise, Holder shall be deemed to have restated each of the representations and warranties in Section 4 of the Warrant as the date thereof
and the Company shall promptly notify the Holder of the number of Shares (or such other securities) issued upon exercise. In the event of a Cash/Public Acquisition where the Fair Market Value of one Share as determined in accordance with
Section 1.3 above would be less than the Warrant Price in effect immediately prior to such Cash/Public Acquisition, then this Warrant will expire immediately prior to the consummation of such Cash/Public Acquisition and shall no longer be
exercisable. Any exercise 

  
 3 

 
of this Warrant after delivery of the Company’s notice as described in Section 3.2(d) below and prior to the consummation of the Acquisition described in such notice shall be deemed to be an
exercise in connection with such Acquisition for purposes of Section 1.2. If such Acquisition is terminated or abandoned prior to the consummation thereof, and unless Holder advised the Company in a written notice that it elects to reaffirm the
exercise, any purported exercise of this Warrant in connection with such Acquisition shall be null and void. 
 (c) Upon and as a condition
to the closing of any Acquisition other than a Cash/Public Acquisition defined above, the Company shall cause the acquiring, surviving or successor entity to assume, and they shall assume, the obligations of this Warrant, and this Warrant shall
thereafter be exercisable for the same class, number and kind securities, cash and/or other property as would have been paid for the Shares issuable upon exercise of the unexercised portion of this Warrant as if such Shares were outstanding as of
immediately prior to the closing of such Acquisition, at an aggregate Warrant Price equal to the aggregate Warrant Price in effect as of immediately prior to such closing, subject to appropriate adjustment and apportionment based upon such
securities, cash and other property in order to protect the economic value of this Warrant immediately prior to such closing, and subject to further adjustment from time to time in accordance with the provisions of this Warrant. 

(d) As used in this Warrant, “Marketable Securities” means securities meeting all of the following requirements,
determined as of immediately prior to the closing of an Acquisition: (i) the issuer thereof is then subject to the reporting requirements of Section 13 or Section 15(d) of the Securities Exchange Act of 1934, as amended (the
“Exchange Act”), and is then current in its filing of all required reports and other information under the Act and the Exchange Act; (ii) the class and series of shares or other security of the issuer that would be
received by Holder in connection with the Acquisition were Holder to exercise this Warrant on or prior to the closing thereof is then traded in a Trading Market, and (iii) Holder would be able to publicly re-sell (free of any contractual, legal
or regulatory restriction), within six (6) months following the closing of such Acquisition, all of the issuer’s shares and/or other securities that would be received by Holder in such Acquisition were Holder to exercise this Warrant in full on
or prior to the closing of such Acquisition. 
 SECTION 2. ADJUSTMENTS TO THE SHARES AND WARRANT PRICE. 

2.1 Stock Dividends, Splits, Etc. If the Company declares or pays a dividend or distribution on the outstanding shares of the
Common Stock payable in securities or property (other than cash), then upon exercise of this Warrant, for each Share acquired, Holder shall receive, without additional cost to Holder, the total number and kind of securities and property which Holder
would have received had Holder owned the Shares of record as of the date the dividend or distribution occurred. If the Company subdivides the outstanding shares of the Common Stock by reclassification or otherwise into a greater number of
shares, the number of Shares purchasable hereunder shall be proportionately increased and the Warrant Price shall be proportionately decreased. If the outstanding shares of the Common Stock are combined or consolidated, by reclassification or
otherwise, into a lesser number of shares, the Warrant Price shall be proportionately increased and the number of Shares shall be proportionately decreased. 

  
 4 

 2.2 Reclassification, Exchange, Combinations or Substitution. Upon any event whereby
all of the outstanding shares of the Common Stock are reclassified, exchanged, combined, substituted, or replaced for, into, with or by Company securities of a different class and/or series, then from and after the consummation of such event, this
Warrant will be exercisable for the number, class and series of Company securities that Holder would have received had the Shares been outstanding on and as of the consummation of such event, and subject to further adjustment thereafter from time to
time in accordance with the provisions of this Warrant. The provisions of this Section 2.2 shall similarly apply to successive reclassifications, exchanges, combinations substitutions, replacements or other similar events. 

2.3 No Impairment. The Company shall not, by amendment of its Certificate of Incorporation or through any reorganization,
recapitalization, transfer of assets, consolidation, merger, share exchange, dissolution, issue, sale of securities, closing of its stockholder books and records, or any other voluntary action, avoid or seek to avoid the observance or performance of
any of the terms to be observed or performed under this Warrant by the company, and shall at all times in good faith assist in carrying out all of the provisions of this Warrant and in taking all such actions as may be necessary or appropriate to
protect Holder’s rights under this Warrant against impairment. 
 2.4 Intentionally Omitted. 

2.5 No Fractional Share. No fractional Share shall be issuable upon exercise of this Warrant and the number of Shares to be issued
shall be rounded down to the nearest whole Share. If a fractional Share interest arises upon any exercise of the Warrant, the Company shall eliminate such fractional Share interest by paying Holder in cash the amount computed by multiplying the
fractional interest by (i) the fair market value (as determined in accordance with Section 1.3 above) of a full Share, less (ii) the then-effective Warrant Price. 

2.6 Notice/Certificate as to Adjustments. Upon each adjustment of the Warrant Price, Common Stock and/or number of Shares, the
Company, at the Company’s expense, shall notify Holder in writing within a reasonable time setting forth the adjustments to the Warrant Price, class and/or number of Shares and facts upon which such adjustment is based. The Company shall,
upon written request from Holder, furnish Holder with a certificate of its Chief Financial Officer, including computations of such adjustment and the Warrant Price, class and number of Shares in effect upon the date of such adjustment. 

SECTION 3. REPRESENTATIONS, WARRANTIES AND COVENANTS OF THE COMPANY. 

3.1 Representations and Warranties. The Company represents and warrants to, and agrees with, the Holder as follows: 

(a) The initial Warrant Price referenced on the first page of this Warrant is not greater than the price per share at which shares of Company
Common Stock or options to purchase shares of Company Common Stock were issued immediately prior to the Issue Date hereof. 

  
 5 

 (b) All Shares which may be issued upon the exercise of this Warrant, and all securities, if any,
issuable upon conversion of the Shares, shall, upon issuance, be duly authorized, validly issued, fully paid and non-assessable, and free of any liens and encumbrances except for restrictions on transfer provided for herein, under the Company’s
Certificate of Incorporation, Bylaws, as amended from time to time, or under applicable federal and state securities laws. The Company covenants that it shall at all times cause to be reserved and kept available out of its authorized and
unissued capital stock such number of shares of the Class, common stock and other securities as will be sufficient to permit the exercise in full of this Warrant and the conversion of the Shares into common stock or such other securities. 

(c) The Company’s capitalization table attached hereto as Schedule 1 is true and complete, in all material respects, as of the Issue
Date. 
 3.2 Notice of Certain Events. If the Company proposes at any time to: 

(a) declare any dividend or distribution upon the outstanding shares of the Company’s stock, whether in cash, property, stock, or other
securities and whether or not a regular cash dividend; 
 (b) offer for subscription or sale pro rata to the holders of the outstanding
shares any additional shares of any class or series of the Company’s stock (other than pursuant to contractual pre-emptive rights); 

(c) effect any reclassification, exchange, combination, substitution, reorganization or recapitalization of the outstanding shares of the
Common Stock; or 
 (d) effect an Acquisition or to liquidate, dissolve or wind up; 

then, in connection with each such event, the Company shall give Holder: 

(1) in the case of the matters referred to in (a) and (b) above, at least ten (10) Business Days prior written
notice of the earlier to occur of the effective date thereof or the date on which a record will be taken for such dividend, distribution, or subscription rights (and specifying the date on which the holders of outstanding shares of the Common Stock
will be entitled thereto) or for determining rights to vote, if any; and 
 (2) in the case of the matters referred to
in (c) and (d) above at least ten (10) Business Days prior written notice of the date when the same will take place (and specifying the date on which the holders of outstanding shares of the Class will be entitled to exchange their
shares for the securities or other property deliverable upon the occurrence of such event and such reasonable information as Holder may reasonably require regarding the treatment of this Warrant in connection with such event giving rise to the
notice). 
 Company will also provide information requested by Holder that is reasonably necessary to enable Holder to comply with Holder’s accounting
or reporting requirements. 

  
 6 

 SECTION 4. REPRESENTATIONS, WARRANTIES AND COVENANTS OF HOLDER. 

The Holder represents, warrants and covenants to the Company as follows: 

4.1 Purchase for Own Account. This Warrant and the Shares to be acquired upon exercise of this Warrant by Holder are being
acquired for investment for Holder’s account, not as a nominee or agent, and not with a view to the public resale or distribution within the meaning of the Act. Holder also represents that it has not been formed for the specific purpose of
acquiring this Warrant or the Shares. 
 4.2 Disclosure of Information. Holder is aware of the Company’s business affairs
and financial condition and has received or has had full access to all the information it considers necessary or appropriate to make an informed investment decision with respect to the acquisition of this Warrant and its underlying
securities. Holder further has had an opportunity to ask questions and receive answers from the Company regarding the terms and conditions of the offering of this Warrant and its underlying securities and to obtain additional information (to
the extent the Company possessed such information or could acquire it without unreasonable effort or expense) necessary to verify any information furnished to Holder or to which Holder has access. 

4.3 Investment Experience. Holder understands that the purchase of this Warrant and its underlying securities involves substantial
risk. Holder has experience as an investor in securities of companies in the development stage and acknowledges that Holder can bear the economic risk of such Holder’s investment in this Warrant and its underlying securities and has such
knowledge and experience in financial or business matters that Holder is capable of evaluating the merits and risks of its investment in this Warrant and its underlying securities and/or has a preexisting personal or business relationship with the
Company and certain of its officers, directors or controlling persons of a nature and duration that enables Holder to be aware of the character, business acumen and financial circumstances of such persons. 

4.4 Accredited Investor Status. Holder is an “accredited investor” within the meaning of Regulation D promulgated under
the Act. 
 4.5 The Act. Holder understands that this Warrant and the Shares issuable upon exercise hereof have not been
registered under the Act in reliance upon a specific exemption therefrom, which exemption depends upon, among other things, the bona fide nature of the Holder’s investment intent as expressed herein. Holder understands that this Warrant
and the Shares issued upon any exercise hereof must be held indefinitely unless subsequently registered under the Act and qualified under applicable state securities laws, or unless exemption from such registration and qualification are otherwise
available. Holder is aware of the provisions of Rule 144 promulgated under the Act. Holder is aware of the provisions of Rule 144 promulgated under the Act. Holder acknowledges that if an exemption from registration or qualification
is available, it may be conditioned on various requirements including, but not limited to, the time and manner of sale, the holding period, and requirements relating to the Company which are outside of Holder’s control, and which the Company is
under no obligation and may not reasonably be able to satisfy. 
 4.6 No Voting Rights; No Stockholder Rights. Holder, as a
Holder of this Warrant, will not have any voting rights or otherwise be entitled to any other rights afforded to a stockholder of the Company until the exercise of this Warrant. 

  
 7 

 SECTION 5. MISCELLANEOUS. 

5.1 Term and Automatic Conversion Upon Expiration. 

(a) Term. Subject to the provisions of Section 1.6 above, this Warrant is exercisable in whole or in part at any time and from time
to time on or before 6:00 PM, Pacific time, on the Expiration Date and shall be void thereafter. 
 (b) Automatic Cashless Exercise
upon Expiration. In the event that, upon the Expiration Date, the Fair Market Value of one Share (or other security issuable upon the exercise hereof) as determined in accordance with Section 1.3 above is greater than the Warrant Price in
effect on such date, then this Warrant shall automatically be deemed on and as of such date to be exercised pursuant to Section 1.2 above as to all Shares (or such other securities) for which it shall not previously have been
exercised. This Warrant shall, to the extent not previously exercised, automatically be deemed to have been fully exercised pursuant to Section 1.2 above (even if not surrendered) as of immediately before any expiration, termination or
cancellation of this Warrant. The Company shall, within a reasonable time, deliver a certificate representing the Shares (or such other securities) issued upon such exercise to Holder. 

5.2 Legends.
 (a) The
Shares (and the securities issuable, directly or indirectly, upon conversion of the Shares, if any) shall be imprinted with a legend in substantially the following form (as well as any other legends required by the Company’s Certificate of
Incorporation, Bylaws, each as amended from time to time): 
 THE SHARES EVIDENCED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE
SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR THE SECURITIES LAWS OF ANY STATE AND, EXCEPT AS SET FORTH IN THAT CERTAIN WARRANT TO PURCHASE STOCK ISSUED BY THE ISSUER TO SILICON VALLEY BANK DATED SEPTEMBER
    , 2016, MAY NOT BE OFFERED, SOLD OR OTHERWISE TRANSFERRED, PLEDGED OR HYPOTHECATED UNLESS AND UNTIL REGISTERED UNDER THE ACT AND APPLICABLE STATE SECURITIES LAWS, OR SUCH OFFER, SALE, TRANSFER, PLEDGE OR HYPOTHECATION IS
PERMITTED UNDER RULE 144 OF THE ACT OR IS EXEMPT FROM SUCH REGISTRATION. 
 (b) Neither this Warrant nor any certificate or instrument
evidencing this Warrant or the Shares shall bear (and the Company hereby agrees to remove or not to affix, as applicable and provided herein) any restrictive or other legend, notice or provision (including without limitation the legend included on
the first page of this Warrant and the legend described in Section 5.2(a) above if (1) a transfer of this Warrant or the Shares is made or proposed to be 

  
 8 

 
made pursuant to SEC Rule 144, (2) a transfer of this Warrant or the Shares, as applicable, are eligible for transfer pursuant to SEC Rule 144(b)(i), (3) a transfer is made or proposed to be made
for no consideration to an affiliate of Holder or has otherwise been made to any affiliate of Holder who is an “accredited investor” as defined in Regulation D promulgated under the Act, or (4) such a legend, notice or provision is not
required in order to establish compliance with any provisions of the Act. Within three (3) trading days of (A) any written request by Holder indicating its intention to make a transfer of this Warrant or all or a portion of the Shares pursuant
to SEC Rule 144, or (B) satisfaction of the registration and prospectus delivery requirements of the Act, the Company shall remove any such legend, notice or provision restricting the sale or transfer of this Warrant or the Shares, as applicable.
Notwithstanding the forgoing or anything to the contrary contained in this Warrant, no certificate or certificates for any Shares purchased acquired hereunder shall bear any restrictive or other legend, notice or provision restricting the sale or
transfer of Shares if, as of the date of any exercise or conversion of this Warrant, the Shares may be transferred pursuant to SEC Rule 144 and, if such sale or transfer cannot, as of such exercise or conversion date, be made, the Company shall
cause any such legend, notice or provision to be removed from all or any such certificates within three (3) trading days of the first date on which such a transfer pursuant to SEC Rule 144 can be made. For all purposes of this Warrant, the
Company shall not be deemed to have delivered to Holder Shares unless and until the Company shall have fully complied with all of the terms and condition of this Section 5.2(b) and Section 5.2(c) below. 

(c) With a view to making available to Holder the benefits of Securities and Exchange Commission (“SEC”) Rule 144 and any
other rule or regulation of the SEC that may at any time permit Holder to sell securities of the Company to the public without registration or pursuant to a registration on Form S-3 (or any other Form that may be available at the time of such
proposed sale), the Company shall, so long as it is subject to the reporting requirements of the Act and the Exchange Act, (1) make and keep available adequate current public information, as those terms are understood and defined in SEC Rule 144, at
all times; (2) use commercially reasonable efforts to file with the SEC in a timely manner all reports and other documents required of the Company under the Act or the Exchange Act; and (3) furnish to Holder, so long as Holder owns the Warrant or
Shares, upon Holder’s request (A) a written statement by the Company that it has complied with the reporting requirements of SEC Rule 144, the Act and the Exchange Act, or that it qualifies as a registrant whose securities may be resold
pursuant to Form S-3 (or any other Form that may be available at the time of such proposed sale), and (B) such other information as may be reasonably requested in availing Holder of any rule or regulation of the SEC that permits the sale of any
securities without registration or pursuant to Form S-3 (or any other Form that may be available at the time of such proposed sale). 
 5.3
Compliance with Securities Laws on Transfer. This Warrant and the Shares issuable upon exercise of this Warrant (and the securities issuable, directly or indirectly, upon conversion of the Shares, if any) may not be transferred or
assigned in whole or in part except in compliance with applicable federal and state securities laws by the transferor and the transferee (including, without limitation, the delivery of investment representation letters and legal opinions reasonably
satisfactory to the Company, as reasonably requested by the Company). The Company shall not require Holder to provide an opinion of counsel if the transfer is to SVB Financial Group (Silicon Valley Bank’s parent company) or any other
affiliate of Holder, provided that any such transferee is an “accredited investor” as defined in Regulation D 

  
 9 

 
promulgated under the Act. Additionally, the Company shall also not require an opinion of counsel if there is no material question as to the availability of Rule 144 promulgated under the
Act; provided that, Holder represents that it has complied with Rule 144 in reasonable detail, the selling broker represents that it has complied with Rule 144, and the Company is provided with a copy of Holder’s notice of proposed sale. 

[5.4 Transfer Procedure. After receipt by Silicon Valley Bank of the executed Warrant, Silicon Valley Bank will transfer all of
this Warrant to its parent company, SVB Financial Group. By its acceptance of this Warrant, SVB Financial Group hereby makes to the Company each of the representations and warranties set forth in Section 4 hereof and agrees to be bound by
all of the terms and conditions of this Warrant as if the original Holder hereof. Subject to the provisions of Section 5.3 and upon providing the Company with written notice, SVB Financial Group and any subsequent Holder may transfer all
or part of this Warrant or the Shares issuable upon exercise of this Warrant (or the securities issuable directly or indirectly, upon conversion of the Shares, if any) to any transferee, provided, however, in connection with any such transfer, SVB
Financial Group or any subsequent Holder will give the Company notice of the portion of the Warrant being transferred with the name, address and taxpayer identification number of the transferee and Holder will surrender this Warrant to the Company
for reissuance to the transferee(s) (and Holder if applicable); and provided further, that any subsequent transferee other than SVB Financial Group shall agree in writing with the Company to be bound by all of the terms and conditions of this
Warrant. Notwithstanding any contrary provision herein, Holder may not, without the Company’s prior written consent, transfer this Warrant or any portion hereof, or any Shares issued upon any exercise hereof, or any shares or other
securities issued upon any conversion of any Shares issued upon any exercise hereof, to any person or entity who directly competes with the Company, except in connection with an Acquisition of the Company by such a direct competitor.] 

5.5 Notices. All notices and other communications hereunder from the Company to the Holder, or vice versa, shall be deemed
delivered and effective (i) when given personally, (ii) on the third (3rd) Business Day after being mailed by first-class registered or certified mail, postage prepaid, (iii) upon actual receipt if given by facsimile or electronic
mail and such receipt is confirmed in writing by the recipient, or (iv) on the first Business Day following delivery to a reliable overnight courier service, courier fee prepaid, in any case at such address as may have been furnished to the
Company or Holder, as the case may be, in writing by the Company or such Holder from time to time in accordance with the provisions of this Section 5.5. All notices to Holder shall be addressed as follows until the Company receives notice
of a change of address in connection with a transfer or otherwise: 
 [Name and address of Holder] 

  
 10 

 Notice to the Company shall be addressed as follows until Holder receives notice of a change in
address: 
  

					
	 CLEARSIDE BIOMEDICAL, INC.
 Attn:
Charles A. Deignan – Chief Financial Officer
 1220 Old Alpharetta Road, Suite 300

Alpharetta, Georgia 30005

	Telephone:	 	  
	 	
	Facsimile:	 	  
	 	
	Email: charlie.deignan@clearsidebio.com

 5.6 Waiver. This Warrant and any term hereof may be changed, waived, discharged or terminated
(either generally or in a particular instance and either retroactively or prospectively) only by an instrument in writing signed by the party against which enforcement of such change, waiver, discharge or termination is sought. 

5.7 Attorney’s Fees. In the event of any dispute between the parties concerning the terms and provisions of this Warrant, the
party prevailing in such dispute shall be entitled to collect from the other party all costs incurred in such dispute, including reasonable attorneys’ fees. 

5.8 Counterparts; Facsimile/Electronic Signatures. This Warrant may be executed in counterparts, all of which together shall
constitute one and the same agreement. Any signature page delivered electronically or by facsimile shall be binding to the same extent as an original signature page with regards to any agreement subject to the terms hereof or any amendment
thereto. 
 5.9 Governing Law. This Warrant shall be governed by and construed in accordance with the laws of the State of
Delaware, without giving effect to its principles regarding conflicts of law. 
 5.10 Headings. The headings in this Warrant are
for purposes of reference only and shall not limit or otherwise affect the meaning of any provision of this Warrant. 
 5.11 Business
Days. “Business Day” is any day that is not a Saturday, Sunday or a day on which Silicon Valley Bank is closed. 

[Remainder of page left blank intentionally] 

[Signature page follows] 

  
 11 

 IN WITNESS WHEREOF, the parties have caused this Warrant to Purchase Common Stock to be executed
by their duly authorized representatives effective as of the Issue Date written above. 
  

			
	“COMPANY”
	
	CLEARSIDE BIOMEDICAL, INC.
		
	By:	 	  

		
	Name:	 	  

		 	(Print)
	Title:	 	
	
	“HOLDER”
		
	By:	 	  

		
	Name:	 	  

		 	(Print)
	Title:	 	

 APPENDIX 1 

NOTICE OF EXERCISE 
 1.
The undersigned Holder hereby exercises its right purchase                  shares of the Common Stock of CLEARSIDE BIOMEDICAL, INC. (the
“Company”) in accordance with the attached Warrant To Purchase Common Stock, and tenders payment of the aggregate Warrant Price for such shares as follows: 

 

	 	[    ]	check in the amount of $         payable to order of the Company enclosed herewith 

  

	 	[    ]	Wire transfer of immediately available funds to the Company’s account 

  

	 	[    ]	Cashless Exercise pursuant to Section 1.2 of the Warrant 

  

							
	[    ]	 	   Other [Describe]	 	  
	  	

 2. Please issue a certificate or certificates representing the Shares in the name specified below: 

 

	
	  

	Holder’s Name
	
	  

	
	  

	(Address)

 3. By its execution below and for the benefit of the Company, Holder hereby restates each of the
representations and warranties in Section 4 of the Warrant to Purchase Common Stock as of the date hereof. 
  

			
	HOLDER:	 	
	
	  

		
	By:	 	  

		
	Name:	 	  

		
	Title:	 	  

		
	(Date):	 	  

 SCHEDULE 1 

Company Capitalization Table

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00262-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00262-of-00352.parquet"}]]